Cor pulmonale

  1. Amores Luque, M.C. 1
  2. Sánchez Vega, J.D. 1
  3. Alonso Salinas, G.L. 1
  4. Zamorano Gómez, J.L. 1
  1. 1 Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades cardiovasculares (I)

Serie: 13

Número: 35

Páginas: 2026-2036

Tipo: Artículo

DOI: 10.1016/J.MED.2021.06.003 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Objetivos de desarrollo sostenible

Resumen

Cor pulmonale refers to structural and functional impairment of the right ventricle due to increased pulmonary vascular pressures, unrelated to left heart disease or congenital heart disease. It is caused by the development of precapillary pulmonary hypertension, pulmonary arterial hypertension being the most common cause of right ventricular dysfunction. The most frequent cause of acute onset is acute pulmonary thromboembolism. Diagnosis requires a high degree of clinical suspicion due to its unspecific symptoms. The initial test indicated is transthoracic echocardiography to assess right ventricular function and estimate pulmonary pressure. If suspected, diagnosis should be confirmed by invasive measurement of pulmonary pressures by right heart catheterisation. Treatment should target the aetiology of pulmonary hypertension, with the targeted therapies that are now available and indicated for each specific group.

Referencias bibliográficas

  • Vonk Noordegraaf A, Groeneveldt JA, Bogaard HJ. Pulmonary hypertension. Eur Respir Rev. 2016;25(139):4-11.
  • Budev MM, Arroliga AC, Wiedemann HP, Matthay RA. Cor pulmonale: an overview. Semin Respir Crit Care Med. 2003 Jun;24(3):233-44.
  • Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913.
  • Southgate L, Machado RD, Gräf S, Morrell NW. Molecular genetic framework underlying pulmonary arterial hypertension. Nat Rev Cardiol. 2020;17(2):85-95.
  • Montani D, Lau EM, Dorfmüller P, Girerd B, Jaïs X, Savale L.Pulmonary veno-occlusive disease. Eur Respir J. 2016;47(5):1518-34.
  • Pugh ME, Sivarajan L, Wang L, Robbins IM, Newman JH, Hemnes AR. Causes of pulmonary hypertension in the elderly. Chest. 2014;146(1):159-66.
  • Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93(3):391-8.
  • Fayngersh V, Drakopanagiotakis F, Dennis McCool F, Klinger JR. Pulmonary hypertension in a stable community-based COPD population. Lung. 2011;189:377.
  • Ismail K, Roberts K, Manning P, Manley C, Hill NS. OSA and pulmonary hypertension: time for a new look. Chest. 2015;147(3):847-61.
  • Rubin LJ. Cor pulmonale revisited. From ferrer and harvey to the present. Ann ATS. 2018;15Suppl1:S42-4.
  • Essien EO, Rali P, Mathai SC. Pulmonary embolism. Med Clin North Am. 2019;103(3):549-64.
  • Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest. 2011;140(1):19-26.
  • Frost A, Badesch D, Gibbs JSR, Gopalan D, Khanna D, Manes A. Diagnosis of pulmonary hypertension. Eur Respir J. 2019;53(1):1801904.
  • Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double blind, randomized, placebo controlled trial. Am J Respir Crit Care Med. 2002;165:800-4.
  • Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;39:589-96.
  • Forfia PR, Fisher MR, Mathai SC, Housten Harris T, Hemnes AR, Borlaug BA. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174:1034-41.
  • Vonk Noordegraaf A, Chin KM, Haddad F, Hassoun PM, Hem-nes AR, Hopkins SR. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur Respir J. 2019;53(1):1801900
  • Grunig E, Tiede H, Enyimayew EO, Ehlken N, Seyfarth HJ, Bossone E. Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension. Circulation. 2013;128:2005-15.
  • Vank Noordegraaf A, Souza R. Cardiac magnetic resonance imaging: What can it add to our knowledge of the right ventricle in pulmonary arterial hypertension? Am J Cardiol. 2012;110:25S-31S.
  • Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889.
  • Montani D, Savale L, Natali D, Jais X, Herve P, García G. Long term response to calcium channel blockers in nonidiopathic pulmonary arterial hypertension. Eur Heart J. 2010;31:1898-907.
  • Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004;61:227-37.
  • Wharton J, Strange JW, Moller GMO, Growcott EJ, Ren X, Franklyn AP. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005;172:105-13.
  • Galie N, Muller K, Scalise AV, Grunig E. Patent Plus: a blinded, randomised and extension study of riociguat plus sildenafil in PAH. Eur Respir J. 2015;45:1314-22.
  • Galie N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near dead to multiple clinical trial meta analyses. Eur Heart J. 2010;31:2080-6.
  • Miravitlles M, Soler Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA. Guía española de la enfermedad pulmonar obs-tructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable. Arch Bronconeumol. 2017;53(6):324-35.
  • Madani MM, Auger WR, Pretorius V, Sakakibara N, Kerr KM, Kim NH. Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2,700 patients. Ann Thorac Surg. 2012;94:97-103.
  • Mayer E, Jenkins D, Lindner J, D’Armini A, Kloek J, Meyns B. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg. 2011;141:702-10.
  • Sugimura K, Fukumoto Y, Satoh K, Nochioka K, Miura Y, Aoki T. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and longtermprognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J. 2012;76:485-8.
  • Velázquez Martín M, Albarrán González Trevilla A, Alonso Charterina S, García Tejada J, Cortina Romero JM. Angioplastia pulmonar con balón en la hipertensión pulmonar tromboembólica crónica no operable. Experiencia inicial en España en una serie de 7 pacientes. Rev Esp Cardiol. 2015;68(6):535-7.
  • Ghofrani HA, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369:319-29.
  • Hoeper MM, Benza RL, Corris P, de Perrot M, Fadel E, Keogh AM. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J. 2019;53(1):1801906.
  • McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc., and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573.
Fuente de los datos: Dialnet